Disclosures: Jessica Burnside: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support, Keyur Patel: Novo-Nordisk: Consultant, Gilead Sciences: Consultant, Merck: Consultant, Resalis: Advisor, Alnoor Ramji: Nothing to Disclose, Mark Swain: Ipsen: Advisor, Abbott: Advisor, Advanz: Advisor, Novo Nordisk: Advisor, GSK: Advisor, Ipsen: clinical trial research grant support, Novo Nordisk: clinical trial research grant support, Madrigal: clinical trial research grant support, Kowa: clinical trial research grant support, Gilead: clinical trial research grant support, Abbvie: clinical trial research grant support, Merck: clinical trial research grant support, Galectin: clinical trial research grant support, Sahar Saeed: Novo Nordisk: Consultant 1174 STATIN USE WITH CARDIOVASCULAR DISEASE AND ALL-CAUSE MORTALITY IN PATIENTS WITH HYPERTENSION, METABOLIC DYSFUNCTIONASSOCIATED LIVER DISEASE, AND OBESITY: A POPULATION-BASED COHORT STUDY Arunkumar Krishnan Faisal Abaalkhail 1 Aldanah Althwanay 2 Tinsay Woreta 3 Saleh Alqahtani 3 , 1 KING FAISAL SPECIALIST HOSPITAL, 2 University of Maryland Medical Center, 3 Johns Hopkins University School of Medicine Background: Cardiovascular (CV) disease remains the leading global cause of disease burden and mortality among patients with metabolic dysfunctionassociated liver disease (MASLD)
Since BPC-157 has not undergone clinical testing in humans, there is no established dosing, no safety profile and no information on potential long-term risks
(2022) 17:e0276879
Blood-brain barrier and bilirubin: clinical aspects and experimental data
Almeida, C
A CD4 + T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate
